Platinum-resistant Ovarian Cancer Recruiting Phase 1 Trials for TILT-123 (DB17519)

Also known as: Platinum drug resistant Ovarian cancer / Platinum-resistant Ovarian Cancer (PROC) / Platinum Resistant Ovarian Cancer

IndicationStatusPhase
DBCOND0068919 (Platinum-resistant Ovarian Cancer)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05271318Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Ovarian CancerTreatment